Related Experiment Videos
Antithrombotic drugs for prevention of recurrent stroke
L Creed Pettigrew1, Sherry Chandler Williams
1Department of Neurology, Stroke Program, Sanders-Brown Center on Aging, University of Kentucky College of Medicine, 101 Sanders-Brown Building, Lexington, Kentucky 40536-0230, USA. cpettigrew@aging.coa.uky.edu
Insights
Aspirin and extended-release dipyridamole combination therapy significantly reduces secondary stroke risk. This combination offers a safer and more effective first-line option for stroke prevention compared to aspirin alone.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Stroke is a leading cause of adult mortality in the U.S.
- Antithrombotic agents are crucial for stroke prevention.
- Aspirin is a common initial therapy for secondary stroke prevention.
Observation:
- Thienopyridines (ticlopidine, clopidogrel) are alternatives to aspirin but lack proven superior efficacy and carry risks like thrombotic thrombocytopenic purpura.
- The combination of aspirin and extended-release dipyridamole (ER-dipyridamole) utilizes multiple mechanisms for stroke risk reduction.
- This combination demonstrates an additive effect compared to monotherapy.
Findings:
- The aspirin and ER-dipyridamole combination showed a twofold increase in risk reduction for secondary stroke.
- The combination therapy exhibited a favorable safety profile.
Implications:
- The combination of aspirin and ER-dipyridamole can be considered a first-line prophylactic agent for secondary stroke prevention.
- This therapeutic strategy offers enhanced efficacy and safety in managing stroke risk.
- Further research may solidify its role in clinical guidelines for post-stroke care.
Abstract:
Stroke is the third most common cause of adult mortality in the United States. Antithrombotic agents form the mainstay of stroke preventive therapy. Aspirin produces a modest reduction in the risk of secondary stroke and is widely recommended for initial administration. The thienopyridines, ticlopidine and clopidogrel, are useful alternatives for secondary stroke prevention in patients who do not respond to or cannot take aspirin. They have not been proven more clinically effective than aspirin and have been associated with thrombotic thrombocytopenic purpura. The combination of aspirin and ER-dipyridamole offers multiple mechanisms of action and an additive effect on stroke risk reduction compared with either agent alone. A twofold increase in risk reduction and a favorable safety profile suggest that the combination can be used as a first-line agent in a prophylactic regimen for secondary stroke.